Jones, Danielle L. https://orcid.org/0000-0003-0372-5579
Kusinski, Laura C.
Gillies, Clare
Meek, Claire L. https://orcid.org/0000-0002-4176-8329
Funding for this research was provided by:
Diabetes UK (17/0005712)
Novo Nordisk Fonden (NNF19SA058974)
European Foundation for the Study of Diabetes (Future leaders' award)
Article History
Received: 3 July 2024
Accepted: 9 October 2024
First Online: 2 December 2024
Acknowledgements
: We thank the participants for their willingness to take part in this study, and the participating study sites and local investigators. The research midwives and nurses who assisted with this study were supported by the NIHR Clinical Research Network (CRN Eastern). This research was supported by the NIHR Cambridge BRC through the Core Biochemistry Assay Laboratory and by the NIHR Leicester BRC. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This study was presented as a poster at the 84th Scientific Sessions of the American Diabetes Association, 21–24 June 2024, Orlando, Florida, USA, and as an oral presentation at the Diabetes in Pregnancy Study Group 56th Annual Meeting, 5–7 September 2024, Örebro, Sweden.
: Data are available from the corresponding author upon request, subject to approval from the sponsor and study steering committee.
: The OPHELIA study was funded by a European Foundation for the Study of Diabetes/Sanofi innovative outcomes project (2017; OPHELIA pilot study). CLM is supported by Diabetes UK through an intermediate clinical fellowship (17/0005712) and by European Foundation for the Study of Diabetes/Novo Nordisk Foundation Future Leader’s Award NNF19SA058974. The funding bodies did not play a role in the design or conduct of the research study. This research was supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre, Leicester Diabetes Centre, University of Leicester, the NIHR Cambridge Biomedical Research Centre (BRC), the Core Biochemical Assay Laboratory (CBAL) and the Core Metabolomic and Lipidomic Laboratory (CMAL). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.
: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
: CLM was responsible for the conceptualisation, design and methodology of the study and for data analysis, and wrote and revised the final report. DLJ was responsible for study coordination, database management, data analysis, and revising several drafts of the manuscript including the final version. LCK supported data collection, study coordination and revised several drafts of the manuscript and the final report. CG provided statistical support and advice and reviewed the various drafts and the final version of the manuscript. Funding for this study was obtained by CLM, who is the guarantor of this study. CLM takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript. All authors reviewed and approved the final version before submission.